Phan VHG(1), Trang Duong HT(2), Tran PT(3), Thambi T(4), Ho DK(5), Murgia X(6). Author information:
(1)Biomaterials and Nanotechnology Research Group, Faculty of Applied Sciences,
Ton Duc Thang University, Ho Chi Minh City 700000, Vietnam.
(2)Department of Pharmaceutical Sciences, University of California, Irvine,
California 92697, United States.
(3)Department of Biochemistry and Cell Biology, Stony Brook University, Stony
Brook, New York 11794-5215, United States.
(4)Department of Bioengineering, Hanyang University, Seoul 04763, South Korea.
(5)Department of Bioengineering, School of Medicine, University of Washington,
Seattle, Washington 98195, United States.
(6)Kusudama Therapeutics, Parque Científico y Tecnológico de Gipuzkoa,
Donostia-San, Sebastián 20014, Spain.
Core-shell structured nanoparticles (NPs) render the simultaneous coloading capacity of both hydrophobic and hydrophilic drugs and may eventually enhance therapeutic efficacy. In this study, we employed a facile squalenoylation technology to synthesize a new amphiphilic starch derivative from partially oxidized starch, which self-assembled into core-shell starch NPs (StNPs) only at a squalenyl degree of substitution (DoS) of ∼1%. The StNPs characteristics could be tuned as the functions of the polymer molecular weight, DoS, and NPs concentration. The biopharmaceutical features of the StNPs, including colloidal stability, carrier properties, and biocompatibility, were carefully investigated. The interaction study between StNPs and mucin glycoproteins, the main organic component of mucus, revealed a moderate mucin interacting profile. Furthermore, the StNPs also showed good penetration through Pseudomonas aeruginosa biofilms. These results nominate StNPs as a versatile drug delivery platform with potential applications for mucosal drug delivery and the treatment of persistent infections.
Having over 250 Research scholars worldwide and more than 400 articles online with open access.